Tag: top
COVID antibody drugs from Lilly and Regeneron won’t do much to...
When Eli Lilly won emergency use authorization for its COVID-19 antibody drug, bamlanivimab, earlier this week, beating Regeneron to the finish line in a...
ESMO: Merck’s Keytruda-chemo combo shows survival ‘trend,’ but can’t top chemo...
Merck’s Keynote-361 study in newly diagnosed metastatic bladder cancer asked a key question: Could adding Keytruda to chemo improve on chemo, the standard of...
ASCO: Roche’s Alecensa stays on top of Xalkori with long-term survival...
Roche made a splash at ASCO three years ago with data showing that its Alecensa could top Pfizer’s Xalkori at keeping ALK-positive lung-cancer at bay....